Clinical Trial Update: Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease [Phase 2]

View source ↗

Summary

The completed Phase 2 double-blind, randomized, placebo-controlled trial evaluated MLN1202 for its effect on C-reactive protein levels in patients with risk fac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• MLN1202

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Atherosclerosis | Phase 2 | Status: COMPLETED